Want to see SE:ATORX full AI Analyst Report?
Top Page
Alligator Bioscience AB
(ATORX)
Select Model
Select Model
Rating:40Underperform
Price Target:
kr0.03
▲(0.00% Upside)
Action:Reiterated
Date:08/28/26
The score is primarily held down by weak financial performance—minimal revenue, large ongoing losses, and substantial cash burn that implies continued funding dependence. Technicals add further pressure, with the price below all key moving averages and negative momentum indicators. Valuation offers limited offset because losses drive a negative P/E and there is no dividend support.
Positive Factors
Improved leverage
The sharp reduction in leverage suggests recapitalization and/or debt reduction, lowering balance-sheet pressure. This provides more financial flexibility than the prior capital structure, although very limited equity still constrains resilience.
Negative Factors
Minimal and declining revenue
Limited and falling revenue confirms that the company lacks meaningful commercial scale and remains dependent on development-stage assets. Without product sales or recurring partner income, operating performance can remain volatile and difficult to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage
The sharp reduction in leverage suggests recapitalization and/or debt reduction, lowering balance-sheet pressure. This provides more financial flexibility than the prior capital structure, although very limited equity still constrains resilience.
Read all positive factors
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr177.57M
Dividend YieldN/A
Average Volume (3M)29.68M
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth-98.81%
EPS Growth80.33%
CountrySE
Employees11
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.06
Shares Outstanding6,909,175,300
10 Day Avg. Volume31,324,379
30 Day Avg. Volume29,681,122
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Alligator Bioscience AB Business Overview & Revenue Model
Company Description
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its ...
How the Company Makes Money
Alligator Bioscience’s business model is typical of clinical-stage biotechnology companies: it develops proprietary drug candidates and seeks to monetize them primarily through partnering rather than through product sales (the company is not known...
Alligator Bioscience AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 514.00K | 514.00K | 57.77M | 58.11M | 35.70M | 12.94M |
| Gross Profit | -23.37M | -54.82M | 57.77M | 58.11M | -112.03M | -74.04M |
| EBITDA | -83.90M | -121.98M | -165.47M | -237.61M | -180.99M | -130.39M |
| Net Income | -77.69M | -51.35M | -233.89M | -248.59M | -193.40M | -141.74M |
Balance Sheet | ||||||
| Total Assets | 65.11M | 110.60M | 104.34M | 118.45M | 169.58M | 333.20M |
| Cash, Cash Equivalents and Short-Term Investments | 16.61M | 62.20M | 64.31M | 66.12M | 97.31M | 278.15M |
| Total Debt | 29.93M | 43.15M | 43.57M | 16.10M | 24.50M | 9.74M |
| Total Liabilities | 61.79M | 103.74M | 234.93M | 106.59M | 80.53M | 50.93M |
| Stockholders Equity | 3.33M | 6.86M | -130.59M | 11.86M | 89.05M | 282.27M |
Cash Flow | ||||||
| Free Cash Flow | -138.83M | -157.45M | -212.43M | -191.74M | -173.05M | -127.08M |
| Operating Cash Flow | -138.83M | -155.99M | -212.43M | -189.28M | -172.61M | -127.03M |
| Investing Cash Flow | 0.00 | 2.21M | 0.00 | -2.46M | -440.00K | -45.00K |
| Financing Cash Flow | 121.72M | 152.59M | 211.27M | 161.56M | -7.83M | 301.80M |
Alligator Bioscience AB Technical Analysis
Neutral
0.03
Price Trends
0.06
Negative
0.10
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
36.52
Neutral
35.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Neutral. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.06, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.52 is Neutral, neither overbought nor oversold. The STOCH value of 35.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ATORX.
Alligator Bioscience AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr504.68M | 2.60 | 63.09% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr190.87M | -8.14 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr719.99M | -2.28 | ― | ― | 87.23% | 35.27% | |
48 Neutral | kr466.87M | -4.11 | -18.05% | ― | ― | 15.97% | |
43 Neutral | kr1.56B | -3.22 | -99.58% | ― | -87.22% | -70.29% | |
40 Underperform | kr177.57M | -0.02 | -736.08% | ― | -98.81% | 80.33% |
* General Sector Average
SE:ATORX
Alligator Bioscience AB
0.03
-0.78
-96.88%
SE:BINV
BioInvent International AB
24.30
-4.20
-14.74%
SE:ONCO
Oncopeptides AB
1.78
-2.74
-60.65%
SE:ELIC
Elicera Therapeutics AB
2.88
-3.91
-57.59%
SE:IMMU
Immunicum AB
7.36
0.36
5.14%
SE:CANTA
Cantargia AB
1.77
-0.78
-30.65%
Alligator Bioscience AB Corporate Events
Alligator Bioscience Restructures Capital and Launches Major Rights Issue
Aug 26, 2026
Alligator Bioscience’s extraordinary general meeting approved multiple changes to its capital structure, including amendments to the Articles of Association and significant reductions of share capital to cover losses and reallocate funds to ...
Alligator Bioscience exits mitazalimab development to refocus on HLX22 royalties and recapitalisation
Aug 26, 2026
Alligator Bioscience reported a weak second quarter with no significant operational events, continuing to post operating losses and declining cash, while progressing investigator-led studies and data presentations for mitazalimab and highlighting ...
Alligator Bioscience Schedules August Earnings Call Amid Strategic Refocus
Aug 20, 2026
Alligator Bioscience will publish its interim report for the April–June 2026 period related to its HER2-targeting activities on 26 August 2026. On the same day, the company will host an earnings webinar and conference call in English, led by...
Alligator Bioscience Calls Extraordinary Meeting to Restructure Capital and Approve Rights Issue
Jul 23, 2026
Alligator Bioscience AB has called an extraordinary general meeting for 26 August 2026 in Lund, where shareholders will vote on a series of capital and governance measures. The agenda includes amendments to the Articles of Association, multiple de...
Alligator Bioscience Shifts Focus to HLX22 and Launches SEK 125.6 Million Rights Issue
Jul 23, 2026
Alligator Bioscience is discontinuing independent development of its lead drug candidate mitazalimab and shifting strategic focus to the HLX22 project, from which it seeks to preserve future royalty potential. The company also plans to wind down r...
Alligator Bioscience Backs Intratumoral Mitazalimab Study in Early Breast Cancer
Jul 2, 2026
Alligator Bioscience has reported the first patient dosed in an investigator-initiated clinical trial of intratumoral mitazalimab in early-stage breast cancer at an Ivy League institution in the United States. The study administers a single intrat...
Alligator Bioscience Sees Revenue Upside as HLX22 Global Phase 3 Reaches Key Milestone
Jun 8, 2026
Alligator Bioscience highlighted progress in a global Phase 3 trial of HLX22, an innovative anti-HER2 monoclonal antibody for gastric cancer developed by Shanghai Henlius Biotech under license from AbClon. The trial has now dosed its first patient...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.